Cancer Biomarker Market Size, Share & Trends Analysis Report, by Type of Biomarker (HER2, MET, EGFR, PD-L1, NTRK, ALK, Novel Biomarkers and Other Biomarkers), Type of Cancer (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkins Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia), By Region, Forecasts, 2025-2034

Report Id: 2563 Pages: 180 Last Updated: 26 May 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of Cancer Biomarker Market-

Cancer Biomarker Market- By Type of Biomarkers

  • HER2
  • MET
  • EGFR
  • PD-L1
  • NTRK
  • ALK
  • Novel Biomarkers
  • Other Biomarkers

Cancer Biomarker Market seg

Cancer Biomarker Market- By Type of Cancer

  • Breast Cancer
  • Prostate Cancer
  • Colorectum Cancer
  • Lung Cancer
  • Thyroid Cancer
  • Bladder Cancer
  • Melanoma
  • Non-Hodgkins Lymphoma
  • Endometrial Cancer
  • Kidney Cancer
  • Leukemia
  • Others

Cancer Biomarker Market- By Region

North America-

  • The US
  • Canada

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Cancer Biomarkers Market Snapshot

Chapter 4. Global Cancer Biomarkers Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Type of Biomarker Estimates & Trend Analysis

5.1. by Type of Biomarker & Market Share, 2024 & 2034

5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Biomarker:

5.2.1. HER2

5.2.2. MET

5.2.3. EGFR

5.2.4. PD-L1

5.2.5. NTRK

5.2.6. ALK

5.2.7. Novel Biomarkers

5.2.8. Other Biomarkers

Chapter 6. Market Segmentation 2: by Type of Cancer Estimates & Trend Analysis

6.1. by Type of Cancer & Market Share, 2024 & 2034

6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Cancer:

6.2.1. Breast Cancer

6.2.2. Prostate Cancer

6.2.3. Colorectum Cancer

6.2.4. Lung Cancer

6.2.5. Thyroid Cancer

6.2.6. Bladder Cancer

6.2.7. Melanoma

6.2.8. Non-Hodgkins Lymphoma

6.2.9. Endometrial Cancer

6.2.10. Kidney Cancer

6.2.11. Leukemia

Chapter 7. Cancer Biomarkers Market Segmentation 6: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Biomarker, 2021-2034

7.1.2. North America Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Cancer, 2021-2034

7.1.3. North America Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

7.2. Europe

7.2.1. Europe Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Biomarker, 2021-2034

7.2.2. Europe Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Cancer, 2021-2034

7.2.3. Europe Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

7.3. Asia Pacific

7.3.1. Asia Pacific Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Biomarker, 2021-2034

7.3.2. Asia Pacific Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Cancer, 2021-2034

7.3.3. Asia Pacific Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

7.4. Latin America

7.4.1. Latin America Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Biomarker, 2021-2034

7.4.2. Latin America Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Cancer, 2021-2034

7.4.3. Latin America Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

7.5. Middle East & Africa

7.5.1. Middle East & Africa Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Biomarker, 2021-2034

7.5.2. Middle East & Africa Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type of Cancer, 2021-2034

7.5.3. Middle East & Africa Cancer Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. Agilent

8.2.2. ARUP Laboratories

8.2.3. BioReference

8.2.4. Foundation Medicine

8.2.5. OncoDNA

8.2.6. Q² Solutions

8.2.7. Thermo Fisher Scientific

8.2.8. YuceBio

8.2.9. Asper Biogene

8.2.10. Caris Life Sciences

8.2.11. CeGaT

8.2.12. Genekor Medical

8.2.13. Guardant Health

8.2.14. Labcorp

8.2.15. MedGenome

8.2.16. NeoGenomics Laboratories

8.2.17. Nonacus

8.2.18. Oxford Gene Technology

8.2.19. Personal Genome Diagnostics

8.2.20. PhenoPath

8.2.21. Positive Biosciences

8.2.22. Quest Diagnostics

8.2.23. Tempus

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
2229
Security Code field cannot be blank!

Frequently Asked Questions

Global Cancer Biomarker Market Size was valued at USD 28.5 Bn in 2024 and is predicted to reach USD 44.5 Bn by 2034

Global Cancer Biomarker Market is predicted to develop at a 4.7% CAGR during the forecast period for 2025-2034.

Labcorp, MedGenome, NeoGenomics Laboratories, Nonacus, Oxford Gene Technology, Personal Genome Diagnostics, PhenoPath, Positive Biosciences, Quest Dia

Type of Biomarkers and Type of Cancer are the key segments of the Cancer Biomarker Market.

North America region is leading the Cancer Biomarker Market
Get Sample Report Enquiry Before Buying